Secondary Logo

Journal Logo

September 2018 - Volume 29 - Issue 8
pp: 717-819

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

Bernier, Cynthia; Soliman, Ahmed; Gravel, Michel; More

Anti-Cancer Drugs. 29(8):774-785, September 2018.

Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands

Franken, Margreet G.; Kanters, Tim A.; Coenen, Jules L.; More

Anti-Cancer Drugs. 29(8):791-801, September 2018.